Phreesia, Inc. (NYSE:PHR) Receives $29.33 Consensus Price Target from Brokerages

by · The Cerbat Gem

Shares of Phreesia, Inc. (NYSE:PHR – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the twelve brokerages that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $29.33.

Several brokerages recently weighed in on PHR. Truist Financial raised their target price on Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Robert W. Baird lowered their price objective on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. Needham & Company LLC reissued a “buy” rating and set a $29.00 target price on shares of Phreesia in a research note on Tuesday, December 10th. JPMorgan Chase & Co. lifted their price target on shares of Phreesia from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Monday, September 9th. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $23.00 price objective on shares of Phreesia in a research note on Friday, September 27th.

View Our Latest Stock Analysis on Phreesia

Insiders Place Their Bets

In related news, General Counsel Allison C. Hoffman sold 1,212 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $21.03, for a total transaction of $25,488.36. Following the transaction, the general counsel now directly owns 119,791 shares of the company’s stock, valued at approximately $2,519,204.73. The trade was a 1.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Michael Weintraub sold 20,565 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $25.04, for a total transaction of $514,947.60. Following the completion of the transaction, the director now owns 242,827 shares in the company, valued at approximately $6,080,388.08. This represents a 7.81 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 90,342 shares of company stock worth $2,041,225. 5.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Versor Investments LP purchased a new stake in shares of Phreesia during the 3rd quarter worth about $694,000. Zacks Investment Management acquired a new stake in Phreesia in the third quarter valued at approximately $631,000. Sei Investments Co. grew its position in Phreesia by 135.3% in the second quarter. Sei Investments Co. now owns 165,327 shares of the company’s stock worth $3,505,000 after acquiring an additional 95,058 shares in the last quarter. State Street Corp increased its stake in shares of Phreesia by 7.1% during the 3rd quarter. State Street Corp now owns 1,327,586 shares of the company’s stock worth $30,256,000 after purchasing an additional 88,517 shares during the last quarter. Finally, Peregrine Capital Management LLC raised its holdings in shares of Phreesia by 11.3% during the 2nd quarter. Peregrine Capital Management LLC now owns 354,607 shares of the company’s stock valued at $7,518,000 after purchasing an additional 36,047 shares in the last quarter. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Phreesia Stock Performance

Shares of NYSE:PHR opened at $25.76 on Friday. The company has a 50 day moving average of $21.30 and a 200-day moving average of $22.18. The company has a current ratio of 1.74, a quick ratio of 1.77 and a debt-to-equity ratio of 0.04. The firm has a market cap of $1.50 billion, a P/E ratio of -17.52 and a beta of 0.98. Phreesia has a twelve month low of $17.07 and a twelve month high of $29.16.

Phreesia (NYSE:PHR – Get Free Report) last released its earnings results on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. The firm had revenue of $106.80 million during the quarter, compared to the consensus estimate of $106.33 million. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The firm’s revenue for the quarter was up 16.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.58) earnings per share. As a group, analysts anticipate that Phreesia will post -1.16 earnings per share for the current fiscal year.

About Phreesia

(Get Free Report

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

Read More